Cancer risks for monoallelic MUTYH mutation carriers with a family history of colorectal cancer.

Cancer risks for a person who has inherited a MUTYH mutation from only one parent (monoallelic mutation carrier) are uncertain. Using the Colon Cancer Family Registry and Newfoundland Familial Colon Cancer Registry, we identified 2,179 first- and second-degree relatives of 144 incident colorectal cancer (CRC) cases who were monoallelic or biallelic mutation carriers ascertained by sampling population complete cancer registries in the United States, Canada and Australia. Using Cox regression weighted to adjust for sampling on family history, we estimated that the country-, age- and sex-specific standardized incidence ratios (SIRs) for monoallelic mutation carriers, compared to the general population, were: 2.

Association between monoallelic MUTYH mutation and colorectal cancer risk: a meta-regression analysis.

Whether people who inherit a mutation in MUTYH from only one parent (monoallelic mutation) are at increased risk of colorectal cancer (CRC) remains controversial. Most previous studies and meta-analyses have not found statistically significant associations but, given carriers are relatively rare, may be underpowered to detect small increased risks. We have conducted a systematic review and meta-regression analysis of previously published case-control studies to estimate the strength of association for monoallelic MUTYH mutation and CRC risk.

Risk factors for colorectal cancer in patients with multiple serrated polyps: a cross-sectional case series from genetics clinics.

Background: Patients with multiple serrated polyps are at an increased risk for developing colorectal cancer (CRC). Recent reports have linked cigarette smoking with the subset of CRC that develops from serrated polyps. The aim of this work therefore was to investigate the association between smoking and the risk of CRC in high-risk genetics clinic patients presenting with multiple serrated polyps.

Phenotypic diversity in patients with multiple serrated polyps: a genetics clinic study.

Objective: Hyperplastic polyposis is a colonic polyposis condition of unknown aetiology. The purpose of this study was to examine the spectrum of phenotypic variation in patients with multiple serrated polyps as a basis for gene discovery.

Methods: One hundred and twenty-six patients with multiple (> or = 5) serrated polyps were recruited to the study.

Cross neutralization of the lethal activities of Myanmar and Thai Russell's viper venoms by Thai and Myanmar antivenoms.

The efficacy of homologous neutralization of the lethal activity of Myanmar Russell's viper venom (MRV) and Thai Russell's viper venom (TRV) by Myanmar antivenom (MAV) and Thai antivenom (TAV), respectively, were studied and compared with the heterologous neutralization of the lethal activity of MRV and TRV by TAV and MAV, respectively, in experimental mice. Although MRV and TRV were the same subspecies, their lethal activities and protective efficacy of MAV and TAV were apparently different from each other. However, there was some extent of cross reactivities between MRV and TAV, and TRV and MAV.

Renal involvement in Russell's viper bite patients without disseminated intravascular coagulation.

We measured urinary beta-N-acetylglucosaminidase (NAG: EC 3.2.1.

Effects of Russell's viper venom on renal lysosomal functions in experimental mice.

The lysosome-enriched fraction of mice kidney was isolated by homogenization and differential centrifugation. Lysosomal functions, namely lysosomal enzyme activities and membrane integrities were investigated in (a) the renal lysosome-enriched fraction, incubated with different concentrations of Russell's viper venom (RVV) for various time intervals (in vitro test) and (b) the kidney homogenate of mice, which had been envenomed with different dosages of RVV and been sacrificed after various time intervals post-envenomation (in vivo test). Three typical marker enzymes for lysosome were used, namely N-acetyl-beta-D-glucosaminidase (NAG), cathepsin D and acid phosphatase.

Clinical trial of intramuscular anti-snake venom administration as a first aid measure in the field in the management of Russell's viper bite patients.

Efficacy of intramuscular anti-snake venom administration immediately after bite as a first aid measure in the field followed by standard hospital management versus standard hospital management alone in the therapy of Russell's viper bite patients was studied. There was a definite reduction in the number of patients with systemic envenomation, complications following disseminated intravascular coagulation and in fatality rate of Russell's viper bite victims who had received first aid intramuscular anti-snake venom prior to hospitalization when compared with those who had not.